Related Experiment Videos

Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues

O Parise1, F Janot, B Luboinski

  • 1Department of Head and Neck Surgery, Institut Gustave-Roussy, Villejuif, France.

Head & Neck
|March 1, 1994
PubMed
Abstract

Insights

Head and neck squamous cell carcinoma (HNSCC) tumors show higher glutathione (GSH) system and thymidylate synthase (TS) activity than normal tissues. These findings offer insights into drug resistance mechanisms for cisplatin and 5-fluorouracil (5-FU) in HNSCC patients.

Area of Science:

  • Biochemistry of cancer
  • Molecular oncology
  • Drug resistance mechanisms

Background:

  • Head and neck squamous cell carcinomas (HNSCC) exhibit variable clinical aggressiveness and chemosensitivity.
  • The glutathione (GSH) system and thymidylate synthase (TS) are implicated in resistance to key HNSCC chemotherapeutics like cisplatin and 5-fluorouracil (5-FU).

Purpose of the Study:

  • To investigate and compare the activity of the GSH system and TS in HNSCC tumors versus adjacent normal mucosa.
  • To correlate these enzymatic activities with clinical parameters of HNSCC.

Main Methods:

  • Spectrophotometric assays for glutathione (GSH) and glutathione S-transferase (GST) activity.
  • Radioassays for thymidylate synthase (TS) activity and folate levels.
  • Analysis of tumor and matched normal mucosa samples from 37 untreated HNSCC patients.

Main Results:

  • Tumors demonstrated significantly higher mean GSH levels (15.2 vs. 8.3 nmol/mg protein) and GST activity (394 vs. 261 nmol/min/mg protein) compared to normal mucosa.
  • TS activity was markedly elevated in tumors (9.2 vs. 0.9 pmol/min/mg protein) across all clinical stages, tumor sizes, and nodal involvement.
  • Folate levels did not differ significantly between tumor and normal mucosa.

Conclusions:

  • Elevated GSH, GST, and TS activities in HNSCC tumors contribute to understanding cisplatin and 5-FU resistance.
  • These findings may aid in predicting tumor behavior and interpatient variability in drug sensitivity for HNSCC.

Related Concept Videos